The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
12
7
2022
medline:
12
10
2022
entrez:
11
7
2022
Statut:
ppublish
Résumé
Antipsychotic polypharmacy in psychotic disorders is widespread despite international guidelines favoring monotherapy. Previous evidence indicates the utility of low-dose partial dopamine agonist (PDAs) add-ons to mitigate antipsychotic-induced metabolic adverse effects or hyperprolactinemia. However, clinicians are often concerned about using PDAs combined with high-potency, full dopaminergic antagonists (FDAs) due to the risk of psychosis relapse. We, therefore, conducted a literature review to find studies investigating the effects of combined treatment with PDAs (i.e. aripiprazole, cariprazine and brexpiprazole) and FDAs having a strong D 2 receptor binding affinity. Twenty studies examining the combination aripiprazole - high-potency FDAs were included, while no study was available on combinations with cariprazine or brexpiprazole. Studies reporting clinical improvement suggested that this may require a relatively long time (~11 weeks), while studies that found symptom worsening observed this happening in a shorter timeframe (~3 weeks). Patients with longer illness duration who received add-on aripiprazole on ongoing FDA monotherapy may be at greater risk for symptomatologic worsening. Especially in these cases, close clinical monitoring is therefore recommended during the first few weeks of combined treatment. These indications may be beneficial to psychiatrists who consider using this treatment strategy. Well-powered randomized clinical trials are needed to derive more solid clinical recommendations.
Identifiants
pubmed: 35815937
doi: 10.1097/YIC.0000000000000417
pii: 00004850-202211000-00006
pmc: PMC9521590
doi:
Substances chimiques
Antipsychotic Agents
0
Dopamine Agonists
0
Dopamine Antagonists
0
Quinolones
0
Thiophenes
0
brexpiprazole
2J3YBM1K8C
Aripiprazole
82VFR53I78
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-275Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Adan-Manes J, Garcia-Parajua P. (2009). Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. J Clin Pharm Ther 34:245–246.
Ahuja N, Lloyd AJ. (2007). Aripiprazole and worsening of psychosis: a case report. J Clin Psychiatry 68:805–806.
Ahuja N, Lloyd AJ. (2008). Worsening of psychosis in a 30 year old man with undifferentiated schizophrenia. Ann Clin Psychiatry 20:113–114.
Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, et al. (2013) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 13:CD006625.
American Psychiatric Association A (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Publishing.
Arciniegas DB. (2015). Psychosis. Continuum (Minneap Minn) 21:715–736.
Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. (2010). Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. CD006633.
Bandelow B, Meier A. (2003). Aripiprazole, a ”Dopamine-Serotonin System Stabilizer” in the treatment of Psychosis. German J Psychiatry 6:9–16.
Barber S, Olotu U, Corsi M, Cipriani A. (2017). Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev 3:CD006324.
Burke MJ, Lincoln J. (2006). Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist. Ann Clin Psychiatry 18:129–130. United States, pp. 129–130.
Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984. Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 34:1529–1540.
Choi YJ. (2015). Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. ScientificWorldJournal 2015:970730.
Chopko TC, Lindsley CW. (2018). Classics in chemical neuroscience: risperidone. ACS Chem Neurosci 9:1520–1529.
Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, Iyo M. (2017). Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psychother Psychosom 86:189–219.
Corena-McLeod M. (2015). Comparative pharmacology of risperidone and paliperidone. Drugs R D 15:163–174.
Corponi F, Serretti A, Montgomery S, Fabbri C. (2017). Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol 32:309–318.
Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, et al. (2019). Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol 29:971–985.
Correll C. (2010a). From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 25:S12–S21.
Correll CU. (2010b). Switching and combining antipsychotics. CNS Spectr 15:8–11.
Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. (2009). Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35:443–457.
Correll CU, Gallego JA. (2012). Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am 35:661–681.
Cunha L, Szigeti K, Mathé D, Metello LF. (2014). The role of molecular imaging in modern drug development. Drug Discov Today 19:936–948.
Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, et al. (2019). SEP-363856, a novel psychotropic agent with a unique, non-D(2) receptor mechanism of action. J Pharmacol Exp Ther 371:1–14.
DeQuardo JR. (2004). Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? J Clin Psychiatry 65:132–133.
Dodd S, F Carvalho A, Puri BK, Maes M, Bortolasci CC, Morris G, Berk M. (2021). Trace amine-associated receptor 1 (TAAR1): a new drug target for psychiatry? Neurosci Biobehav Rev 120:537–541.
Domenico BD, Michele F, Nicola S, Stefano M, Monica P, Marilde C, et al. (2014). Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole. Recent Pat Endocr Metab Immune Drug Discov 8:30–37. pp. 30–37.
Dreimüller N, Lieb K, Tadić A, Engelmann J, Wollschläger D, Wagner S. (2019). Body mass index (BMI) in major depressive disorder and its effects on depressive symptomatology and antidepressant response. J Affect Disord 256:524–531.
Evernden C, Giang I, Anderson M. (2021). The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia. Ment Health Clin 11:305–310.
Frankel JS, Schwartz TL. (2017). Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 7:29–41.
Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. (2012). Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138:18–28.
Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. (2016). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 50:410–472.
Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ (2010). International consensus study of antipsychotic dosing Am. J. Psychiatry 167:686–693.
Germann D, Kurylo N, Han F. (2012). Risperidone. Profiles Drug Subst Excip Relat Methodol 37:313–361.
Green B. (1999). Focus on olanzapine. Curr Med Res Opin 15:79–85.
Green B. (1999). Focus on quetiapine. Curr Med Res Opin 15:145–151.
Grover S, Sharan P, Gupta N. (2006). Aripiprazole worsens psychosis: a case report. Prim Care Companion J Clin Psychiatry 8:380–381.
Gupta B, Chee KS, Neo LQ, Tang C, Hariram J, Tan GC, et al. (2021). Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial. Ther Adv Psychopharmacol 11:20451253211046765.
Hajjo R, Setola V, Roth BL, Tropsha A (2012) Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers. J Med Chem 55:5704–5719.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al.; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. (2012). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318–378.
Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, et al. (2009). Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 29:165–169.
Heres S, Kraemer S, Bergstrom RF, Detke HC. (2014). Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. Int Clin Psychopharmacol 29:299–312.
Huang WL, Chang LR. (2012). Hyperhidrosis under combination of zotepine and haloperidol alleviated by aripiprazole. Psychiatry Clin Neurosci 66:245.
Hughes JP, Rees S, Kalindjian SB, Philpott KL. (2011). Principles of early drug discovery. Br J Pharmacol 162:1239–1249.
Huhtala T, Poutiainen P, Rytkönen J, Lehtimäki K, Parkkari T, Kasanen I, et al. (2019). Improved synthesis of [(18)F] fallypride and characterization of a Huntington’s disease mouse model, zQ175DN KI, using longitudinal PET imaging of D2/D3 receptors. EJNMMI Radiopharm Chem 4:20.
Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, et al. (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171–181.
Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y (2007) Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 572:160–170.
Jarema M, Bieńkowski P, Heitzman J, Parnowski T, Rybakowski J. (2017). Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia. Psychiatr Pol 51:7–21.
Jovanović M, Vučićević K, Miljković B. (2020). Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models. Drug Metab Rev 52:1–18.
Kanahara N, Takase M, Sasaki T, Honma M, Fujita Y, Tadokoro S, et al. (2020). The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. Int Clin Psychopharmacol 35:338–344.
Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, et al. (2009). A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 70:1348–1357.
Kantrowitz JT, Srihari VH, Tek C. (2007). Resolution of tardive dyskinesia after addition of aripiprazole to haloperidol depot. J Clin Psychopharmacol 27:525–526.
Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. (1998). 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921–928.
Kapusta ND, Mossaheb N, Barnas C, Fischer P. (2007). Aripiprazole-induced psychosis: a case report of reexposure by stepwise up-titration. J Clin Psychiatry 68:1445–1446.
Katona L, Czobor P, Bitter I. (2014). Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophr Res 152:246–254.
Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al.; (Systematic Review). (2020). The American psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 177:868–872.
Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A. (2020). A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med 382:1497–1506.
Koszła O, Targowska-Duda KM, Kędzierska E, Kaczor AA. (2020). In Vitro and In Vivo models for the investigation of potential drugs against schizophrenia. Biomolecules 10:E160.
Kuo J, Hwu HG. (2008). Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient. Clin Neuropharmacol 31:173–175.
Lea JW, Stoner SC, LaFollette J. (2007). Agitation associated with aripiprazole initiation. Pharmacotherapy 27:1339–1342.
Lecamwasam DL, Alexander J. (2011). Aripiprazole associated hyponatraemia. Aust N Z J Psychiatry 45:686–687.
Leo R, Razzini C, Di Lorenzo G, Bianchi F, Tesauro M, Zanasi M, et al. (2008). Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol. J Clin Psychiatry 69:327–328.
Li FL, Yeh TC, Yang FC, Liang CS. (2019). Combined typical and atypical long-acting injectable antipsychotics in treatment-resistant schizophrenia: two cases. Psychiatry Clin Neurosci 73:140.
Li P, Snyder GL, Vanover KE. (2016). Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Top Med Chem 16:3385–3403.
Lieberman JA. (2004). Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18:251–267.
Lieberman JA, First MB. (2018). Psychotic disorders. N Engl J Med 379:270–280.
Lin SK. (2020). Antipsychotic polypharmacy: a dirty little secret or a fashion? Int J Neuropsychopharmacol 23:125–131.
Mahgoub N. (2015). Does combining aripiprazole with other antipsychotics worsen psychosis? J Clin Psychopharmacol 35:470–471.
Mailman RB, Murthy V. (2010). Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 16:488–501.
Marazziti D, Piccinni A, Baroni S, Mungai F, Presta S, Mucci F, Dell’Osso L. (2016). Current trends on antipsychotics: focus on asenapine. Curr Med Chem 23:2204–2216.
Nair PC, Miners JO, McKinnon RA, Langmead CJ, Gregory KJ, Copolov D, et al. (2021). Binding of SEP-363856 within TAAR1 and the 5HT(1A) receptor: implications for the design of novel antipsychotic drugs. Molecular Psychiatry 27:88–94.
NICE Clinical Guidelines No 178 (2014). Psychosis and schizophrenia in adults: prevention and management. National Institute for Health and Care Excellence (NICE).
Noorani N, Hadi F, Ahmadkhaniha HR. (2016). 29 year old man with multiple sclerosis and schizophrenia: a case report. Electron Physician 8:3409–3411. pp. 3409–3411.
Okhuijsen-Pfeifer C, Huijsman EAH, Hasan A, Sommer IEC, Leucht S, Kahn RS, Luykx JJ. (2018). Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr Scand 138:281–288.
van Os J, Reininghaus U. (2016). Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry 15:118–124.
Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS. (2021). Consideration of long-acting injectable antipsychotics for polypharmacy regimen in the treatment of schizophrenia: put it on the table or not? Clin Psychopharmacol Neurosci 19:434–448.
Peuskens J. (2011). The management of schizophrenia: focus on extended-release quetiapine fumarate. Neuropsychiatr Dis Treat 7:549–564.
Porcelli S, Balzarro B, Serretti A. (2012). Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 22:165–182.
Raja M. (2007). Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol 10:107–110.
Ramaswamy S, Vijay D, William M, Pirzada Sattar S, Praveen F, Petty F. (2004). Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 19:45–48.
Rancans E, Dombi ZB, Mátrai P, Barabássy Á, Sebe B, Skrivele I, Németh G. (2021). The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study. Int Clin Psychopharmacol 36:154–161.
Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. (2017). Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry 62:604–616.
Roth BL, Lopez E, Patel S, Kroeze WK. (2000). The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? Neuroscientist 6:252–262.
Russell G, Reinfeld S, Kam O, Lee G, Weiss M, Mathew Koola M. (2022). Case series on aripiprazole and dopamine supersensitivity psychosis. Int Clin Psychopharmacol 37:122–128.
Sathyanarayana Rao TS, Andrade C. (2016). Classification of psychotropic drugs: problems, solutions, and more problems. Indian J Psychiatry 58:111–113.
Schrimpf LA, Aggarwal A, Lauriello J. (2018). Psychosis. Continuum (Minneap Minn) 24:845–860.
Shahid M, Walker GB, Zorn SH, Wong EHF (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23:65–73.
Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. (2000). Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152:174–180.
Snyder GL, Vanover KE, Davis RE, Li P, Fienberg A, Mates S (2021) A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. Adv Pharmacol 90:253–276.
Sonnenschein SF, Gill KM, Grace AA. (2019). State-dependent effects of the D(2) partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia. Neuropsychopharmacology 44:572–580.
Stahl SM. (2016). Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr 21:1–6.
Stahl SM. (2016). Mechanism of action of cariprazine. CNS Spectr 21:123–127.
Stahl SM. (2017). Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes. CNS Spectr 22:375–384.
Stahl SM. (2001). Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, ‘Goldilocks’ actions at dopamine receptors. J Clin Psychiatry 62:841–842.
Stahl SM. (2008). Do dopamine partial agonists have partial efficacy as antipsychotics? CNS Spectr 13:279–282.
Stahl SM. (2012). Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand 125:349–351.
Stahl SM. (2021). Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press.
Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M. (2015). Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol 29:383–389.
Taylor DM, Barnes TRE, Young AH. (2021). The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines Series.
Tiihonen J, Taipale H, Mehtälä J, Vattulainen P, Correll CU, Tanskanen A. (2019). Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry 76:499–507.
Varnäs K, Varrone A, Farde L. (2013). Modeling of PET data in CNS drug discovery and development. J Pharmacokinet Pharmacodyn 40:267–279.
Wang LJ, Ree SC, Huang YS, Hsiao CC, Chen CK. (2013). Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 40:260–266.
Weiden PJ. (2006). Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 20:104–118.
Wenthur CJ, Lindsley CW. (2013). Classics in chemical neuroscience: clozapine. ACS Chem Neurosci 4:1018–1025.
Yazici E, S Cilli A, Yazici AB, Baysan H, Ince M, Bosgelmez S, et al. (2017). Antipsychotic use pattern in schizophrenia outpatients: correlates of polypharmacy. Clin Pract Epidemiol Ment Health 13:92–103.
Zohar J, Stahl S, Moller HJ, Blier P, Kupfer D, Yamawaki S, et al. (2015). A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol 25:2318–2325.
Zohar J, Kasper S. (2016). Neuroscience-based Nomenclature (NbN): a call for action. World J Biol Psychiatry 17:318–320.